BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

Sanofi

French drug maker Sanofi SA will manufacture 125 million doses of the COVID-19 vaccine co-developed by Pfizer Inc and BioNTech SE in its Frankfurt plant starting this summer.

Sanofi To Manufacture 125 Million COVID-19 Vaccine Doses For Rival Pfizer-BioNTech

Pfizer will supply the US with 200 million doses of its coronavirus vaccine two months sooner than expected, according to the firm's chief executive. Pfizer CEO Albert Bourla said the US, which bought 200 million initial vaccine doses from the firm last year, will get the shipment two months earlier than expected after the FDA changed changed labels to account for "extra doses" in vials.

Pfizer will supply the US with 200 million COVID-19 vaccine doses 2 months sooner than expected due to 'extra' doses extracted from vials (PFE)

No need to let Covid-19 vaccine distribution issues deter you from owning Pfizer stock as the company still stands to earn massive revenues. The post Hold Your Pfizer Shares Despite Hiccups in Vaccine Rollout appeared first on InvestorPlace.

Hold Your Pfizer Shares Despite Hiccups in Vaccine Rollout

Working with top vaccine stocks like Pfizer and BioNTech, MRVI stock is among the best IPO stocks to buy and watch as it enters a new buy zone. The post Breakout Watch: IPO Leader, Pfizer Vaccine Partner MRVI Stock Enters Buy Zone appeared first on Investor's Business Daily.

Breakout Watch: IPO Leader, Pfizer Vaccine Partner MRVI Stock Enters Buy Zone

Pfizer (PFE) and BioNTech inks an agreement with COVAX to supply up to 40 million doses of their COVID-19 vaccine, BNT162b2.

Pfizer (PFE) to Supply 40M Doses of Coronavirus Vaccine to COVAX

MAINZ, Germany and SHANGHAI, China, 25 Jan. 2021 /PRNewswire/ -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health...

BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine

"The bottom line here is that this is a very scarce resource. We need to make sure every dose gets used," Dr. Scott Gottlieb, who sits on the board of Pfizer, said.

Pfizer board member Gottlieb defends change to ship fewer Covid vaccine vials

The German biotech appears to be in pretty good shape.

COVID Vaccine Stocks: How Strong Is BioNTech's Financial Position?

The COVID-19 vaccine made by Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX) has been approved by Australia's Therapeutic Goods Administration, Reuters reported Monday (Sydney Time). What Happened: Inoculation of Pfizer's vaccine is likely to commence in late February at 80,000 doses per week, Australia's Health Minister Greg Hunt told reporters.

Pfizer COVID-19 Vaccine Gets Approved In Australia

White House chief of staff Ron Klain said Sunday that he didn't think it was possible for states to purchase Covid-19 vaccines directly from manufacturers.

White House says U.S. states can't directly purchase Covid vaccine under emergency use authorization

The biotech's pipeline includes many promising candidates.

BioNTech's Potential Winners Beyond Its COVID Vaccine

Pfizer's Covid-19 vaccine is authorized for people age 16 and older. The company's trial in kids 12-15 is now fully enrolled, a key step for use in kids.

Pfizer says its Covid vaccine trial for kids ages 12 to 15 is fully enrolled

AstraZeneca

Bank of America

Johnson & Johnson

Moderna

Moderna and Pfizer/BioNTech should rake in similar levels of revenue for their vaccines.

Top Coronavirus Vaccine Makers Will Earn Up to $23 Billion in Revenue This Year, Says New Analysis

The CDC says the two products are not interchangeable, but it added in updated guidance posted Thursday that it's OK to mix the shots in rare circumstances.

CDC quietly changes Covid vaccine guidance to OK mixing Pfizer and Moderna shots in 'exceptional situations'

Pfizer will supply up to 40 million doses of its coronavirus vaccine to a global alliance aiming to provide poor nations with coronavirus vaccines, the World Health Organization said Friday.

Pfizer to supply up to 40 million doses to WHO-backed global Covid vaccine program

BioNTech SE and Pfizer Inc. said Friday that they plan to sell 40 million doses of their COVID-19 vaccine this year to Covax, a group that aims to ensure 92 lower-income countries have access to coronavirus vaccines. BioNTech's stock gained 1.2% in trading on Friday, while shares of Pfizer were up 0.3%.

BioNTech, Pfizer to sell 40 million doses to lower-income countries

NEW YORK CITY, NY and MAINZ, GERMANY, January 22 , 2021 (GLOBE NEWSWIRE) — Pfizer and BioNTech SE today announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021.

Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19

Norway's medicines authority said there might be a link between vaccination and the deaths of several elderly people.

WHO Says Pfizer-BioNTech Covid-19 Vaccine Is Safe For The Elderly After Norway Questioned Its Role In Numerous Deaths

The partners could supply the WHO with coronavirus vaccine doses for lower-income countries.

Pfizer and BioNTech to Supply WHO's COVID-19 Vaccine Program

PFE stock never enjoyed the same run-up in the Covid-19 vaccine race as its competitors, even though it crossed the finish line first. The post For Pfizer, the Covid-19 Vaccine ‘Honeymoon' Is Over appeared first on InvestorPlace.

For Pfizer, the Covid-19 Vaccine ‘Honeymoon' Is Over

European countries should use all available vaccine doses provided by biotech firm BioNTech and its partner Pfizer because there will be enough for the requisite second booster shot due to a planned production ramp-up, BioNTech's largest investor said.

BioNTech investor, amid worry over shortage, vows vaccines to be delivered for second shot

A new study bolsters confidence in the mRNA vaccine.

Pfizer and BioNTech Report Evidence That Their Vaccine Is Effective Against COVID-19 Variant

The coronavirus vaccine developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) works against a new strain of coronavirus that appeared in the U.K., according to a preprint made available before publication. What Happened: The B.1.1.7 strain is unlikely to escape BNT162b2-mediated protection, according to the preprint.

Pfizer-BioNTech Vaccine Found Effective Against New Coronavirus Strain In Lab Study

New York and Mainz, Germany, January 20, 2021 — Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine BNT162b2 to neutralize the SARS-CoV-2 U.K. strain, also known as B.1.1.7 lineage or VOC 202012/01. The results were published on the preprint server bioRxiv and submitted to a peer-reviewed journal.

Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture

The Covid vaccine developed by Pfizer-BioNTech is likely to be effective against a mutant strain of the virus that was first discovered in the U.K.

News for BioNTech SE Stock (BNTX)